Benchmark raises its price target to $27 on Buy-rated Bio-Reference Labs BRLI as the company's earnings gear on BRLI's transitions from development to launch.
Benchmark notes, "We believe earnings and cash flow are benefiting from improving operating leverage as new products advance from development to launch. The OnkoMatch tumor genotyping program was launched in January and BRLI's Inherigen panethnic carrier screening panel is scheduled to be launched during the current fiscal
quarter. Expanded investment to develop these programs weighed on gross margin throughout most of F2011. We believe gross margin and overall profitability improved as product development activity diminished in FQ1 and F4Q."
BRLI closed at $22.28 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in